EUVIMEDEUVIMED entdecken
Crossref

The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma

Soichi Takeda, Tadashi Namisaki, Aritoshi Koizumi, Hiroaki Takaya, Yuki Tsuji, Akihiko Shibamoto, Satoshi Iwai, Takashi Inoue, Yukihisa Fujinaga, Norihisa Nishimura, Shinya Sato, Koh Kitagawa und 4 weitere

Anticancer Research · 2025

DOI: 10.21873/anticanres.17797 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Soichi Takeda und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Antigens, Differentiation, Myelomonocytic, Liver Neoplasms, Carcinoma, Hepatocellular, Receptors, Cell Surface.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: This study aimed to identify predictors of therapeutic response to atezolizumab plus bevacizumab (Atez/Bev) in patients with advanced hepatocellular carcinoma (aHCC). PATIENTS AND METHODS: Of the 39 patients included in the study, 28 underwent a lactulose-mannitol test. Intestinal permeability (IP) was evaluated using the lactulose-to-mannitol ratio (LMR), serum soluble CD163 (sCD163), and soluble mannose receptor (sMR). The therapeutic response and its correlation with IP were evaluated. RESULTS: The median progression-free survival (PFS) and overall survival (OS) were 208 and 489 days, respectively. Regarding the best achieved treatment response, the objective response rate and disease control rate (DCR) were 39.2% and 67.8%, respectively, based on the Response Evaluation Criteria in Solid Tumors 1.1. The LMR was significantly higher in those with progressive disease (PD group) than in those achieving complete response, partial response, and stable disease [disease control (DC) group]. The optimal LMR cutoff was 5.24 for predicting ORR and PD. The low-LMR group showed significantly longer PFS than the high-LMR group. sCD163 and sMR were significantly higher in the PD group than in the DC group. sCD163 was found to be significantly associated with the DCR [odds ratio (OR)=14.3, 95%CI=1.47-138, p=0.022]. The patients were divided into two groups according to their median CD163 levels. The low-CD163 group showed significantly longer PFS and OS than the high-CD163 group. CONCLUSION: IP was associated with Atez/Bev response in HCC. sCD163 could be a predictive marker of Atez/Bev response in patients with aHCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, Differentiation, MyelomonocyticLiver NeoplasmsCarcinoma, HepatocellularReceptors, Cell SurfaceAntigens, CDAntibodies, Monoclonal, HumanizedBevacizumabMacrophage ActivationAntineoplastic Combined Chemotherapy ProtocolsHumansCD163 AntigenMaleFemaleMiddle AgedAgedAdultBiomarkers, TumorLectins, C-TypeMannose ReceptorTreatment Outcome

Stichwörter der Autor:innen

Biomarkerhepatocellular carcinomaimmune checkpoint inhibitorintestinal permeability

Substanzen

CD163 AntigenAntigens, Differentiation, MyelomonocyticReceptors, Cell SurfaceAntigens, CDAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabBiomarkers, TumorLectins, C-TypeMannose Receptor

Autor:innen und Institutionen

  • Department of Gastroenterology, Nara Medical University, Nara, Japan.
  • Department of Gastroenterology, Nara Medical University, Nara, Japan; tadashin@naramed-u.ac.jp.
  • Department of Evidence-Based Medicine, Nara Medical University, Nara, Japan.
  • Clinical Research Center, Nara Medical University, Nara Medical University, Nara, Japan.

Zitieren

APA

Takeda, S., Namisaki, T., Koizumi, A., Takaya, H., Tsuji, Y., Shibamoto, A., Iwai, S., Inoue, T., Fujinaga, Y., Nishimura, N., Sato, S., Kitagawa, K., Kaji, K., Mitoro, A., Asada, K., & Yoshiji, H. (2025). The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17797

Vancouver

Takeda S, Namisaki T, Koizumi A, Takaya H, Tsuji Y, Shibamoto A, et al. The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma. Anticancer Research. 2025. doi:10.21873/anticanres.17797

BibTeX
@article{Takeda2025,
  author = {Takeda, Soichi and Namisaki, Tadashi and Koizumi, Aritoshi and Takaya, Hiroaki and Tsuji, Yuki and Shibamoto, Akihiko and Iwai, Satoshi and Inoue, Takashi and Fujinaga, Yukihisa and Nishimura, Norihisa and Sato, Shinya and Kitagawa, Koh and Kaji, Kosuke and Mitoro, Akira and Asada, Kiyoshi and Yoshiji, Hitoshi},
  title = {The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17797}
}
Kostenlos starten →